2Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol, 1995; 147(1):9.
3Fan ZN, Isobe K, Kiuchi K oet al. Enhancement of nitric oxide production from activated macrophages by a purified form of ginsenoside (Rg1). Am J Chin Med, 1995; 23(3-4) :279.
4Imamura F, Horai T, Mukai M, et al. Serum requirement for in vitro invasion by tumor cells. Jpn J Cancer Res, 1991; 82(5):493.
5Folkman J. Clinical application of research on angiogenesis.New Engl J Med, 1995; 333(26):1757.
6Thompson WD, William WL, Maragoudakis M, et al. The clinical manipulation of angiogenesis: pathology, slde-effects,surprise and opportunities with novel human therapies. J Pathol, 2000; 190(3) :330.
7Gasparini G, Harris A. Clinical importance of the determination of tumor angiogenesis in breast carcinoma ; much more than a new prognostic tool. J Clin Oncol, 1995; 139(3) :765.
8O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastasis by a Lewis lung carcinoma. Cell, 1994; 79(2):315.
9Slaton JW, Perotte P, Inoue K, et al. Interferon alpha mediated down regulation of angiogenesis related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res, 1999; 5 (10):2726.
10Relf M, Lejeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor,acidic and basic fibroblast growth factor,tumout growth bl,platlet-derived endothelial cell growth factor, placental growth factor and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res, 1997 ; 57(5) ; 963.
